PLM-402

PLM-402 is a preclinical small molecule candidate developed by Pelemed for the treatment of chronic Hepatitis B virus (HBV) infection. It is designed with a dual mechanism of action, functioning as both a Class 1 Capsid Assembly Modulator (CAM) and an inhibitor of the Sodium/taurocholate cotransporting polypeptide (NTCP). As a Class 1 CAM, PLM-402 interferes with the viral replication cycle by inducing the formation of aberrant, non-functional polymers instead of proper nucleocapsids. Simultaneously, by targeting NTCP—the primary entry receptor for HBV and Hepatitis D virus (HDV) on hepatocytes—the drug aims to block the infection of healthy liver cells. This combined approach is intended to reduce the viral reservoir and prevent the spread of the virus, potentially offering a more effective treatment for chronic HBV patients.